Overview

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Status:
Terminated
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The study was designed to find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs was more effective for treating pancreatic cancer than using gemcitabine alone.
Phase:
Phase 2
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Treatments:
Gemcitabine